Assessing Adverse Events From Investigational Dose of Semaglutide Injection for Type 2 Diabetes

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses what some of the adverse events experienced by patients with type 2 diabetes were during the trial, and how patients were able to handle them.